BioElectronics receives product approvals
This article was originally published in The Tan Sheet
Executive SummaryHealth Canada approves BioElectronics Corp.'s Allay Menstrual Pain Therapy product for OTC sale to treat menstrual pain symptoms. The Frederick, Md.-based company also announces June 29 that South Korea's regulators approved its ActiPatch for reducing muscle pain. "With its proven technology and established clinical platform, Allay and ActiPatch are very unique brands in both Canada and Korea," the company said. BioElectronics noted the approvals open doors into new markets. The firm's pain relief products already are available in 44 countries worldwide
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.